Ibrutinib and venetoclax treatment, ETI, disease response, and survival for 23 patients with R/R MCL. Individual patient data are shown in lanes, ordered by duration on study, with key molecular variants detected in corresponding MCL biopsy from each patient at baseline shown to left of the graph. The full molecular data on each MCL sample have previously been fully reported.15 A black square shows the presence of a pathogenic variant for the indicated genes; for TP53 this includes deletions. Arrows at the end of each lane indicate ongoing treatment on study or ongoing surveillance in ETI. Patient 8 elected to come off study treatment while in MRD-negative CR but declined to enter ETI due the logistic constraints of the surveillance schedule. CR, complete response documented by PET; MRD Neg, minimal residual disease negative on BM by flow cytometry, PD; IB, ibrutinib; IB+V, ibrutinib plus venetoclax; PR, partial response with PET; VEN, venetoclax.
